9 2 7 l e t t e r s Pilocytic astrocytoma, the most common childhood brain tumor 1 , is typically associated with mitogen-activated protein kinase (MAPK) pathway alterations 2 . Surgically inaccessible midline tumors are therapeutically challenging, showing sustained tendency for progression 3 and often becoming a chronic disease with substantial morbidities 4 . Here we describe whole-genome sequencing of 96 pilocytic astrocytomas, with matched RNA sequencing (n = 73), conducted by the International Cancer Genome Consortium (ICGC) PedBrain Tumor Project. We identified recurrent activating mutations in FGFR1 and PTPN11 and new NTRK2 fusion genes in non-cerebellar tumors. New BRAF-activating changes were also observed. MAPK pathway alterations affected all tumors analyzed, with no other significant mutations identified, indicating that pilocytic astrocytoma is predominantly a single-pathway disease. Notably, we identified the same FGFR1 mutations in a subset of H3F3A-mutated pediatric glioblastoma with additional alterations in the NF1 gene 5 . Our findings thus identify new potential therapeutic targets in distinct subsets of pilocytic astrocytoma and childhood glioblastoma.
l e t t e r s medulloblastoma [10] [11] [12] and for several other pediatric solid tumors 13 . The average number of small insertion-deletion alterations (indels) affecting coding sequences was <1 per case. All coding somatic SNVs and indels are listed in Supplementary Table 2 .
In line with other tumor types 10, 14, 15 , pilocytic astrocytomas had genome-wide mutation rates that positively correlated with the age of the affected individual (r = 0.42; P = 2.3 × 10 −5 , Pearson's productmoment correlation; Supplementary Fig. 2a ). The observed mutations were predominantly cytosine-to-thymine transitions at CpG sites (likely arising from deamination of methylated cytosines), suggesting that the age-dependent increase in mutation frequency may largely be due to background processes occurring in progenitor cells before tumorigenesis, as recently reported in leukemia 15 ( Supplementary Fig. 2b) .
Most of the known events activating the MAPK pathway were also found in our series, including KIAA1549-BRAF fusion variants (70 cases), a FAM131B-BRAF fusion 16 , 4 BRAF V600E mutations and 1 BRAF ins599T alteration (Supplementary Table 1 ). Three tumors were associated with neurofibromatosis type 1. This prevalence is lower than would be expected for prospective cohorts (5-10%), as material for biological studies from these typically optic pathway-associated tumors is limited. NF1 has been reported to follow a classical tumor suppressor model in pilocytic astrocytoma, with a somatic second hit in addition to a germline alteration 9 . This model also held true in our series (Supplementary Table 1) .
Analysis of copy number and structural alterations using DNA and RNA sequencing identified four new BRAF fusions ( Fig. 1 and  Supplementary Fig. 3 ). As expected, all variants resulted in loss of the N-terminal regulatory region of BRAF. An RNF130-BRAF fusion derived from a reciprocal t(5;7)(q35;q34) translocation was seen in two cases (Fig. 1a) , with single examples identified of CLCN6-BRAF, MKRN1-BRAF and GNAI1-BRAF fusions (Supplementary Fig. 3a-c) . Thus, non-KIAA1549-BRAF fusions comprise a notable minority of activating events, with BRAF seeming to be a promiscuous fusion partner.
Another new BRAF alteration was identified in ICGC_PA65, resulting in a three-amino-acid insertion (p.Arg506_insValLeuArg, insVLR) in the interdomain cleft of BRAF-a structural region linked to BRAF activity 17 and homodimerization 18 . Protein modeling predicted that the insertion of these residues stabilizes a dimeric form of BRAF (known to be active independent of RAS stimulation 19 ) (Fig. 1b) . Homodimerization was confirmed by immunoprecipitation, and the BRAF insVLR mutant increased extracellular signalregulated kinase (ERK) phosphorylation as effectively as the BRAF V600E mutant (Fig. 1c,d) .
New alterations in KRAS were also observed. ICGC_PA117 and ICGC_PA142 both showed two distinct mutations (encoding p.
[Glu63Lys]+[Arg73Met] and p.
[Leu19Phe]+[Gln22Lys], respectively). DNA and RNA sequencing data confirmed that both alterations affected the same allele ( Supplementary Fig. 4) . Although there are reports of double KRAS mutations in entities such as colon cancer 20 , these typically involve at least one hotspot residue (codon 12, 13 or 61) and often represent heterogeneous tumor subclones rather than two hits in one allele (although this has also been described; for example, see ref. 21 ). The alterations identified in our tumors did not encompass classical mutational hotspots, suggesting that further characterization of downstream effects is warranted.
All but one of the cerebellar tumors in our series harbored a BRAF fusion, with this one exception having a KRAS alteration. Nine of 48 (19%) of the non-cerebellar tumors, however, lacked the above alterations. Further assessment of structural rearrangements identified two new gene fusions in a total of three samples, involving the region encoding the kinase domain of NTRK2 (also known as TrkB)-an oncogene implicated in the tumorigenesis of neuroblastoma, among other cancers 22, 23 . The related NTRK1 and NTRK3 genes have previously been shown to be activated by fusion events (for example, TPM3-NTRK1 in papillary thyroid cancer 24 and ETV6-NTRK3 in multiple tumors 25 ). The QKI-NTRK2 and NACC2-NTRK2 fusions identified here were verified by PCR ( Fig. 2 and Supplementary Fig. 3d ). Both 5′ partners contained regions encoding dimerization domains and are therefore predicted to induce ligandindependent dimerization. Notably, N-terminal TrkB truncation has recently been shown to induce transformation of neural crest cells 26 . 
e t t e r s
The downstream effects of TrkB activation are mediated, at least in part, via MAPK pathway activation 27 . A second new recurrent alteration, namely, mutation of two hotspots (codons for Asn546 and Lys656) within the kinase domain of FGFR1, was seen in five tumors (Fig. 3a and Supplementary  Table 3) . FGFR1 is more commonly activated through amplification in tumors such as breast 28 and lung 29, 30 cancer. Occasional FGFR1 mutations have been observed in adult glioblastoma (GBM) 31, 32 , a highly malignant astrocytoma, as have FGFR1-TACC1 or FGFR3-TACC3 fusion genes 33 . Mutations in homologous codons in FGFR2 and FGFR3 are commonly found in other tumor types, particularly bladder, skin and endometrial cancers (see the Catalogue of Somatic Mutations in Cancer (COSMIC) database 34 ). Both mutations result in midbrain hyperproliferation in developing chick embryos 35 . The p.Asn546Lys variant alters FGFR1 autophosphorylation, resulting in higher kinase activity and transforming potential 36 , whereas the p.Lys656Glu variant is also transforming in vitro 37 . Notably, the latter study suggested that fibroblast growth factor 2 (FGF2, also known as bFGF) ligand was necessary in addition to FGFR1 mutation to maintain neurosphere formation in vitro. Gene expression array data of 118 pilocytic astrocytomas, including 66 from the present series, showed significantly increased FGF2 expression in pilocytic astrocytomas compared with 158 other astrocytic tumors 38, 39 or normal tissues 40 . This increase was not restricted to only FGFR1-mutant or wild-type tumors, suggesting that ligand-mediated pathway activation may have a general role in tumorigenesis (Fig. 3b) . Immunohistochemical detection of phosphorylated FGFR1 showed strong, diffuse positivity in all seven pilocytic astrocytomas harboring an FGFR1 mutation for which material was available. No positivity was observed in 11 tumors with wild-type FGFR1. All samples showed strong staining for phosphorylated ERK (Supplementary Fig. 5 ). Notably, ICGC_PA89 harbored an alternative alteration in FGFR1 consisting of a ~4.5-kb internal tandem duplication (ITD) of the portion of the gene encoding the kinase domain, reminiscent of the activating internal tandem duplications of the FLT3 kinase observed in acute myeloid leukemia 41 (Fig. 3c) .
Further recurrent mutations were found in the phosphatase gene PTPN11 (also called SHP-2) encoding a RAS-MAPK-related adaptor protein (Fig. 3d) . Both encoded alterations (p.Glu69Lys and p.Glu76Ala) were previously reported in juvenile monomyelocytic leukemia, which is frequently associated with SHP-2 activation 42, 43 . Notably, both alterations were found in FGFR1-mutant tumors (ICGC_PA84 and ICGC_PA166), suggesting a cooperative role of these factors in tumorigenesis (Supplementary Table 3) . Overexpression of mutant SHP-2 alone did not elevate the levels of phosphorylated ERK in vitro, whereas the two FGFR1 mutants, either alone or in combination with mutant SHP-2, upregulated the levels of phosphorylated ERK (Supplementary Fig. 6 ). This finding supports the hypothesis that PTPN11 mutation alone is insufficient for pilocytic astrocytoma development but may have a modifying role in FGFR1-mutant tumors. Of note, PTPN11 expression was higher in pilocytic astrocytomas compared with other astrocytomas or normal tissues (Fig. 3e) , suggesting that this phosphatase has a broader role in the biology of this entity. An additional cohort of 45 non-cerebellar pilocytic astrocytomas, negative for KIAA1549-BRAF fusion, was screened for FGFR1 (exons 12 and 14) and PTPN11 (exon 3) mutations. Nine cases harbored FGFR1 mutations encoding a p.Asn546 or p.Lys656 alteration, and one additionally carried a PTPN11 mutation encoding a p.Glu69Lys change (Supplementary Table 3) , confirming our whole-genome sequencing findings. Germline PTPN11 mutations are one of the causes of the hereditary developmental disorders Noonan syndrome 44 and multiple lentigines syndrome (also known as LEOPARD syndrome) 45 . A few case reports have described pilocytic astrocytomas occurring in individuals with these syndromes [46] [47] [48] [49] . Thus, together with NF1, there are three known 'RASopathies' , characterized by germline MAPK pathway mutations 50 , linked with pilocytic astrocytoma tumorigenesis. In our germline sequencing data, however, NF1 was the only RASopathy-related gene disrupted at a higher frequency than in the 1000 Genomes Project (see URLs).
Notably, all of the pilocytic astrocytomas in our cohort harbored a MAPK pathway alteration. BRAF, FGFR1, KRAS and NF1 were the only genes found to be significantly mutated using the Genome MuSiC algorithm (see URLs; Supplementary Table 4) . With the exception of FGFR1 and PTPN11, each case typically harbored only one pathway alteration (P < 0.0001, permutation test; Fig. 4) . Together with the finding that BRAF kinase activation alone is sufficient to induce pilocytic astrocytomas in mice 51, 52 , these data strongly support the concept of pilocytic astrocytoma as a prototypic single-pathway disease driven by a limited number of oncogenic hits (possibly only one in some cases; Supplementary Fig. 7) .
One of the FGFR1-mutant tumors (ICGC_PA69) also had an H3F3A mutation encoding a p.Lys27Met alteration and somatic mutations of NF1-both of which are more commonly encountered in pediatric GBM 5 . Three experienced neuropathologists agreed on pilocytic astrocytoma histology for this case, although a diagnosis of GBM cannot be conclusively excluded, owing to limited material. By examining previous exome sequencing data for pediatric GBM 5 , we identified 3 of 48 samples (6%) with an FGFR1 mutation. Notably, all three harbored the same constellation of an H3F3A p.Lys27Met alteration, a somatic NF1 alteration and FGFR1 activation (Supplementary Table 3 ). They were also wild type for TP53, which is mutated in most GBMs or diffuse intrinsic pontine gliomas 5, 53 with the H3F3A p.Lys27Met alteration. One tumor reported in a targeted sequencing cohort of medulloblastoma 10 npg l e t t e r s with an H3F3A p.Lys27Met alteration, an NF1 alteration and an FGFR2 p.Lys659Glu alteration (homologous to FGFR1 p.Lys656Glu), making a total of five cases with this combination. Gene expression analysis indicated that this tumor was likely a GBM previously misclassified as medulloblastoma. It is not currently clear why these alterations occur in concert, and additional work will be required to assess their roles. One possibility is that NF1 mutation may mimic elevated PTPN11 expression, as activation of SHP-2 inhibits the recruitment of Ras GTPase-activating proteins (RasGAPs, including NF1) to the plasma membrane 54 . All FGFR1-mutant tumors were extracerebellar, mostly in midline locations (Supplementary Table 3) , suggesting a link between cell of origin and/or microenvironment with FGFR1-driven tumorigenesis. The H3F3A p.Lys27Met alteration is also associated with midline GBM 39 . Notably, FGFR1 has a role in neural stem cell self-renewal 55 and is essential for midline glial cell development 56 . This spatial clustering may also reflect differential sensitivity of distinct neural precursors to activating stimuli, particularly NF1 loss 57, 58 . The type and timing of second hits (H3F3A or NF1 mutation) and/or the differentiation stage of the cell of origin may contribute to determining a fate of oncogeneinduced senescence and slow growth (pilocytic astrocytoma) 59, 60 versus aggressive malignancy with poor outcome (GBM).
In summary, this study has provided new insights into the tumorigenesis of pilocytic astrocytoma. Each tumor harbored very few mutations, in keeping with generally benign behavior. Our findings confirm the concept that pilocytic astrocytomas are predominantly PA (118) DA (20) AA (43) K27 GBM (13) G34 GBM (11) IDH1 GBM (12) Other pediatric GBM ( Ig II  Ig III  TM  TK1  TK2  TK1′  TK2′ dup ( 
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Other BRAF fusion BRAF mutation PTPN11 mutation KRAS mutation NF1 mutation NTRK2 fusion Figure 4 Summary of MAPK pathway alterations in pilocytic astrocytoma. An overview of MAPK pathway alterations identified in the 96 whole-genome sequencing cases included in the present study, indicating the mutual exclusivity of the majority of these hits (with the exception of ones affecting FGFR1 and PTPN11); P < 0.0001, permutation test on 10,000 iterations. Each column represents one tumor sample. Red boxes indicate that a given alteration is present in this sample. The blue box represents FGFR1-ITD rather than a point mutation. The yellow box indicates a BRAF p.Glu451Asp alteration in a case with a KIAA1549-BRAF fusion (of unknown functional significance but included in the exclusivity testing). The black/red split boxes represent one germline and one somatic NF1 alteration per case.
npg l e t t e r s driven by aberrant activation of the MAPK pathway. Most notably, however, we report new recurrent mutations in NTRK2, FGFR1 and PTPN11, which were mutually exclusive with other RAF and RAS changes. Combined with the observation of FGF2 and PTPN11 overexpression, these results indicate upstream contributors to MAPK pathway activation in this entity. Emerging preclinical data suggest that BRAF inhibitors may trigger paradoxical activation in tumors harboring KIAA1549-BRAF fusions, that is, the majority of pilocytic astrocytomas 61 . Single-drug or combination therapy with FGFR, NTRK2 and/or MAPK/ERK kinase (MEK) inhibitors, several of which are currently in preclinical and clinical trials [62] [63] [64] , may therefore represent rational treatment options. BRAF V600E -specific agents may also be a logical choice for ~5% of patients. Finally, the identification of recurrent FGFR1 mutations in a subset of pediatric GBMs provides an opportunity for the therapeutic targeting of FGFR signaling in these clinically challenging brain tumors.
